DISCOVERY OF A NOVEL ADJUVANT FOR ORAL VACCINE FORMULATIONS

CELESTE PUEBLAS CASTRO; LORENA CORIA; LAURA BRUNO; LUCAS SAPOSNIK; PHILIPPE HERMAND; STEPHANE TEMMERNAND; KARINA PASQUEVICH; JULIANA CASSATARO

Congreso; Reunión Anual de sociedades de Biociencias; 2022

Sociedades Biomédicas Argentina

In our laboratory, we have shown that U-Omp19 from Brucella spp. is an oral vaccine adjuvant because it can inhibit gastrointestinal proteases while it induces adaptive immune responses. To our knowledge there are no other reports describing the use of protease inhibitors from bacteria as vaccine adjuvants. Thus, to discover new oral adjuvants we performed an in-silico and in vivoscreening of different bacterial protease inhibitors where Ecotin from Salmonella spp. was selected as a candidate. Here, we evaluate if this protease inhibitor could be used as an adjuvant for oral vaccines. For this aim, we orally immunized BALB/c or C57BL/6 mice with two different viral antigens (Ags) simultaneously or both co-administered with Ecotin. When co-administered with the Ags, Ecotin induced a sustainable specific IgA response in feces compared to the administration of Ags alone (p